Sera Prognostics (NASDAQ:SERA) versus Arrowhead Pharmaceuticals (NASDAQ:ARWR) Head-To-Head Contrast

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Sera Prognostics (NASDAQ:SERA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, valuation and profitability.

Institutional and Insider Ownership

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Volatility & Risk

Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Sera Prognostics has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500.

Profitability

This table compares Arrowhead Pharmaceuticals and Sera Prognostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Sera Prognostics	-47,475.72%	-46.71%	-34.06%

Valuation and Earnings

This table compares Arrowhead Pharmaceuticals and Sera Prognostics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$669.50 million	12.38	-$1.63 million	($2.25)	-26.15
Sera Prognostics	$70,000.00	1,144.02	-$31.93 million	($0.67)	-3.03

Arrowhead Pharmaceuticals has higher revenue and earnings than Sera Prognostics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations for Arrowhead Pharmaceuticals and Sera Prognostics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1	3	10	1	2.73
Sera Prognostics	1	0	1	1	2.67

Arrowhead Pharmaceuticals presently has a consensus price target of $99.07, suggesting a potential upside of 68.37%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 170.94%. Given Sera Prognostics’ higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Arrowhead Pharmaceuticals.

Summary

Arrowhead Pharmaceuticals beats Sera Prognostics on 8 of the 14 factors compared between the two stocks.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.